In particular, slower progression of kidney disease and lower rates of clinically relevant renal events have been reported for empagliflozin in the prospective empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes (EMPA-REG OUTCOME) trial [167] comparing the administration of SGLT2 inhibitor with placebo. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.